Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug
by Arpita Dutt
Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
Can Intercept (ICPT) Beat Estimates this Earnings Season?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.
Will Radius Health (RDUS) Disappoint this Earnings Season?
by Zacks Equity Research
Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.
Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Is a Beat in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.
Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?
by Zacks Equity Research
Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.
What to Expect from Keryx (KERX) this Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Is a Beat in Store for Alexion (ALXN) this Earnings Season?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval
by Zacks Equity Research
Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs
by Arpita Dutt
Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.
Gilead (GILD) Application for HIV Drug Validated in EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.
Gilead (GILD) Application for HIV Drug Validated in EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.
Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal
by Arpita Dutt
Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.
J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.
The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric
Top Stock Reports for Wells Fargo, Broadcom & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Broadcom (AVGO) and Gilead (GILD).
Galapagos-Gilead Begin Phase II Study on Uveitis Candidate
by Zacks Equity Research
Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.